Delbart, W.; Marin, G.; Stamatopoulos, B.; de Wind, R.; Sirtaine, N.; Demetter, P.; Vercruyssen, M.; Woff, E.; Karfis, I.; Ghanem, G.E.;
et al. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Cancers 2023, 15, 2332.
https://doi.org/10.3390/cancers15082332
AMA Style
Delbart W, Marin G, Stamatopoulos B, de Wind R, Sirtaine N, Demetter P, Vercruyssen M, Woff E, Karfis I, Ghanem GE,
et al. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Cancers. 2023; 15(8):2332.
https://doi.org/10.3390/cancers15082332
Chicago/Turabian Style
Delbart, Wendy, Gwennaëlle Marin, Basile Stamatopoulos, Roland de Wind, Nicolas Sirtaine, Pieter Demetter, Marie Vercruyssen, Erwin Woff, Ioannis Karfis, Ghanem E. Ghanem,
and et al. 2023. "Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE" Cancers 15, no. 8: 2332.
https://doi.org/10.3390/cancers15082332
APA Style
Delbart, W., Marin, G., Stamatopoulos, B., de Wind, R., Sirtaine, N., Demetter, P., Vercruyssen, M., Woff, E., Karfis, I., Ghanem, G. E., Flamen, P., & Wimana, Z.
(2023). Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Cancers, 15(8), 2332.
https://doi.org/10.3390/cancers15082332
